Margaret A. Tempero

28.8k total citations · 7 hit papers
195 papers, 11.3k citations indexed

About

Margaret A. Tempero is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Margaret A. Tempero has authored 195 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 57 papers in Cancer Research and 34 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Margaret A. Tempero's work include Pancreatic and Hepatic Oncology Research (104 papers), Cancer Genomics and Diagnostics (54 papers) and Neuroendocrine Tumor Research Advances (28 papers). Margaret A. Tempero is often cited by papers focused on Pancreatic and Hepatic Oncology Research (104 papers), Cancer Genomics and Diagnostics (54 papers) and Neuroendocrine Tumor Research Advances (28 papers). Margaret A. Tempero collaborates with scholars based in United States, Germany and Spain. Margaret A. Tempero's co-authors include Andrew H. Ko, Anna Falanga, Juan I. Arcelus, Gary H. Lyman, Alok A. Khorana, Nicole M. Kuderer, Christopher R. Flowers, Edward P. Balaban, Nigel S. Key and Ajay K. Kakkar and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Nature Medicine.

In The Last Decade

Margaret A. Tempero

185 papers receiving 11.1k citations

Hit Papers

Pancreatic cancer 2011 2026 2016 2021 2016 2011 2015 2019 2013 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pancreatic cancer
    2016 1.3k citations Margaret A. Tempero et al. profile →
  2. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
    2011 1.2k citations Eric A. Collisson, Peter Olson et al. profile →
  3. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
    2015 968 citations Gary H. Lyman, Kari Bohlke et al. Journal of Clinical Oncology profile →
  4. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
    2019 934 citations Nigel S. Key, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  5. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2013 544 citations Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  6. Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
    2015 381 citations Andrew J. Gunderson, Megan M. Kaneda et al. Cancer Discovery profile →
  7. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update
    2023 135 citations Nigel S. Key, Alok A. Khorana et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Margaret A. Tempero United States 45 6.7k 2.6k 2.5k 2.3k 2.2k 195 11.3k
Dick J. Richel Netherlands 43 4.5k 0.7× 2.2k 0.9× 3.5k 1.4× 1.6k 0.7× 750 0.3× 107 9.6k
Afshin Dowlati United States 54 9.5k 1.4× 2.4k 0.9× 6.0k 2.4× 890 0.4× 672 0.3× 395 16.2k
Gordon Rustin United Kingdom 67 5.3k 0.8× 1.5k 0.6× 4.0k 1.6× 3.4k 1.5× 402 0.2× 245 16.0k
Giampietro Gasparini Italy 43 4.1k 0.6× 3.4k 1.3× 5.0k 2.0× 707 0.3× 607 0.3× 170 9.8k
Frederick R. Rickles United States 49 1.2k 0.2× 734 0.3× 1.8k 0.7× 1.3k 0.6× 4.4k 2.0× 125 10.3k
William T. Creasman United States 66 2.9k 0.4× 920 0.4× 1.4k 0.6× 3.8k 1.6× 501 0.2× 243 17.4k
David S. Mendelson United States 41 2.0k 0.3× 652 0.3× 2.5k 1.0× 709 0.3× 661 0.3× 188 7.1k
Werner Scheithauer Austria 57 14.5k 2.2× 2.3k 0.9× 2.2k 0.9× 4.1k 1.8× 352 0.2× 350 18.2k
George Fountzilas Greece 54 7.7k 1.2× 2.1k 0.8× 3.1k 1.3× 2.3k 1.0× 164 0.1× 576 12.8k
Scot C. Remick United States 38 2.8k 0.4× 559 0.2× 1.5k 0.6× 656 0.3× 652 0.3× 156 6.1k

Countries citing papers authored by Margaret A. Tempero

Since Specialization
Citations

This map shows the geographic impact of Margaret A. Tempero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret A. Tempero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret A. Tempero more than expected).

Fields of papers citing papers by Margaret A. Tempero

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret A. Tempero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret A. Tempero. The network helps show where Margaret A. Tempero may publish in the future.

Co-authorship network of co-authors of Margaret A. Tempero

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret A. Tempero. A scholar is included among the top collaborators of Margaret A. Tempero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret A. Tempero. Margaret A. Tempero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Walker, Evan J., Dena Goldberg, Julia Carnevale, et al.. (2021). Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. The Oncologist. 26(11). e1982–e1991. 23 indexed citations
2.
Key, Nigel S., Alok A. Khorana, Nicole M. Kuderer, et al.. (2019). Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 38(5). 496–520. 934 indexed citations breakdown →
3.
Tempero, Margaret A., Do‐Youn Oh, Teresa Macarulla, et al.. (2019). Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. Annals of Oncology. 30. iv126–iv126. 16 indexed citations
4.
Walker, Evan J., Julia Carnevale, Amie Blanco, et al.. (2018). Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Familial Cancer. 18(2). 241–251. 22 indexed citations
5.
Tempero, Margaret A.. (2017). Introduction: Pancreatic Adenocarcinoma. The Cancer Journal. 23(6). 309–309. 3 indexed citations
6.
Draanen, Jenna van, Pamela L. Davidson, H Bour, et al.. (2016). Assessing Researcher Needs for a Virtual Biobank. Biopreservation and Biobanking. 15(3). 203–210. 17 indexed citations
7.
Kunz, Pamela L., Raymond R. Balise, Louis Fehrenbacher, et al.. (2016). Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors. Pancreas. 45(10). 1394–1400. 50 indexed citations
8.
Tempero, Margaret A., Lisa M. Coussens, Lawrence Fong, et al.. (2016). A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).. Journal of Clinical Oncology. 34(15_suppl). TPS2601–TPS2601. 8 indexed citations
9.
Ko, Andrew H., Tanios Bekaii‐Saab, Jessica Van Ziffle, et al.. (2015). A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research. 22(1). 61–68. 100 indexed citations
10.
Zill, Oliver A., Claire Greene, Dragan Sebisanovic, et al.. (2015). Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discovery. 5(10). 1040–1048. 202 indexed citations
11.
Lyman, Gary H., Kari Bohlke, Alok A. Khorana, et al.. (2015). Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. Journal of Clinical Oncology. 33(6). 654–656. 968 indexed citations breakdown →
12.
Gunderson, Andrew J., Megan M. Kaneda, Takahiro Tsujikawa, et al.. (2015). Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discovery. 6(3). 270–285. 381 indexed citations breakdown →
13.
Ko, Andrew H., Margaret A. Tempero, Wu‐Chou Su, et al.. (2013). A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. British Journal of Cancer. 109(4). 920–925. 126 indexed citations
14.
Cinar, Pelin & Margaret A. Tempero. (2012). Monoclonal Antibodies and Other Targeted Therapies for Pancreatic Cancer. The Cancer Journal. 18(6). 653–664. 15 indexed citations
15.
Ko, Andrew H., Alan P. Venook, Emily K. Bergsland, et al.. (2010). A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology. 66(6). 1051–1057. 66 indexed citations
16.
Hann, Byron, Donghui Wang, Stephan Gysin, et al.. (2007). Lipidic nanoparticle CPT-11 in a bioluminescent orthotopic pancreas cancer model. Cancer Research. 67. 5648–5648. 5 indexed citations
17.
Engstrom, P, Al B. Benson, Adam J. Cohen, et al.. (1996). NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network.. PubMed. 10(11 Suppl). 140–75. 50 indexed citations
18.
Haga, Yoshio, Margaret A. Tempero, & Rowen K. Zetterman. (1996). Unconjugated bilirubin inhibits in vitro cytotoxic T lymphocyte activity of human lymphocytes. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1317(1). 65–70. 38 indexed citations
19.
Kessinger, Anne, Michael R. Bishop, JR Anderson, et al.. (1995). Comparison of Subcutaneous and Intravenous Administration of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization. Journal of Hematotherapy. 4(2). 81–84. 5 indexed citations
20.
Herlyn, Dorothee, Henry F. Sears, Dimitrios Iliopoulos, et al.. (1986). Anti-idiotypic antibodies to monoclonal antibody CO17-1A.. PubMed. 5 Suppl 1(34). 21–8. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dick J. Richel Breakdown of academic impact, for papers by Afshin Dowlati Breakdown of academic impact, for papers by Gordon Rustin Breakdown of academic impact, for papers by Giampietro Gasparini Breakdown of academic impact, for papers by Frederick R. Rickles Breakdown of academic impact, for papers by William T. Creasman Breakdown of academic impact, for papers by David S. Mendelson Breakdown of academic impact, for papers by Werner Scheithauer Breakdown of academic impact, for papers by George Fountzilas Breakdown of academic impact, for papers by Scot C. Remick
Rankless by CCL
2026